Condition: Advanced Solid Tumors · Sponsor: TCRx Therapeutics Co.Ltd
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
This description comes directly from the study's public registry record.
Weichi Zhou · +86-18994103369 · zhouwc@tcrximmune.cn
Always discuss trial participation with your own doctor first.
| Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07596693